Efficacy and Safety of HRS9531 Injection in Obese Subjects Without Diabetes
Status:
Not yet recruiting
Trial end date:
2024-04-30
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and dose-response relationship of HRS9531 injection compared with
placebo in reducing body weight in obese subjects without diabetes after 24 weeks of
treatment.